Izinzuzo kanye nemiphumela emibi
I-Hydroxyzine iyisizukulwane sokuqala, idala antihistamine , okusho ukuthi inemiphumela emibi efanayo ku-Benadryl . Ithengiswa ngaphansi kwegama elithi Atarax neVistaril kodwa futhi litholakala ngesimo esijwayelekile. I-Hydroxyzine yasungulwa ekuqaleni njengama-sedative phakathi neminyaka yama-1950 kodwa yatholwa ukuthi inezinto ezibalulekile ze-antihistamine.
I-Hydroxyzine ye-Allergies
I-Hydroxyzine isetshenziselwa ukwelashwa kwezimo ezihlukahlukene zokugula, ikakhulukazi imifuba , kodwa futhi isetshenziselwa ukuphatha i- itching , ukukhathazeka, ukulala, kanye nokucabangela nokuhlanza.
Umthamo we-hydroxyzine uncike esimweni esiphathwayo, nakuba umthamo ovamile ungama-milligram angu-25 kuya kwangu-50 njalo emahoreni ayisithupha. I-Hydroxyzine isetshenziselwa izingane, nakuba umthamo ubalwa ngokusekelwe kwesisindo somntwana. Kodwa-ke, imiphumela ye-sedation nokulalaza kungaholela ekutheni umuthi we-antihistamine wesibili wesizukulwane njenge-Xyzal (levocetirizine.)
Indlela Hydroxyzine Isebenza Ngayo Imithi Yomzimba
I-Hydroxyzine isebenza ngokuvimbela i-H1 receptor, ebopha kubo futhi yehlisa umsebenzi we-histamine. I-Histamine ivumela uketshezi oluthe xaxa ukuthi lubalekele kuma-capillaries abe yizicubu, futhi yilolu buketshezi obhekana njengempumpi ephuthumayo namazombe uma unesifo esiphundu. I-Histamine iphinde iholele ukuvuvukala nokukhiqizwa kwamasondo ezindaweni ezihlukumezayo.
Ngokuvimbela i-H1 receptor, i-hydroxyzine iyasebenza ngokumelene nalezi zimpawu zokungezwani. Lokhu kungasiza futhi ngenkathi kutholakala (pruritis) kubangelwa izifo.
Kodwa i-hydroxyzine ibuye ibuyele ebuchosheni lapho ineminye imiphumela eyabangela ukulala nokuduma. Le miphumela ingase ingasetshenziswanga uma ilapha imithi.
I-Second-Generation Antihistamines Elandelwa Hydroxyzine
I-metabolite esebenzayo ye-hydroxyzine yi- cetirizine (i-Zyrtec) , etholakala ngaphezu kwe-counter njenge-antihistamine ephansi.
I-isomer esebenzayo ye-cetirizine iyi- levocetirizine (i-Xyzal) , etholakala kuphela nge-prescription futhi isatholakala efomu elijwayelekile. Ayifinyelele ebuchosheni kalula njengoba i-hydroxyzine, ngakho-ke ayiyikukhiqiza i-sedation efanayo. Futhi ayikhiqizi imiphumela yokulwa nokukhathazeka kwe-hydroxyzine ngesizathu esifanayo.
U-Zyrtec no-Xyzal bangcono ukwelashwa kwe-rhinitis ye-allergen kune-hydroxyzine ngoba banemiphumela emibi kakhulu futhi isikhathi eside. Zibuye zisebenze ekwelapheni imifantu nokuluma.
I-Zyrtec ne-Xyzal ayinamandla ekwelapheni ukukhathazeka, ukulala noma ukuhlanza, nokuhlanza, izimo lapho i-hydroxyzine noma enye i-antihistamine yesizukulwane sokuqala ingabekwa khona. (Naphezu kwe-hydroxyzine engumuthi oneminyaka engu-50 ubudala, usazuzisa ukwelashwa kwezimo ezihlukahlukene zezokwelapha.)
Ukubuyekezwa kwezifundo ze-Xyzal (levocetirizine) ngo-2009 kwathola ukuthi u-5 mg / d wayesebenza kahle ekunciphiseni izimpawu zenkinga ye-allergenic ( hay fever ), i-rhinitis yokugula okuhlala isikhathi eside, kanye ne-idiopathic urticaria engapheliyo, ukuthuthukisa ikhwalithi ukuphila, nephrofayli yokubekezelelana eyamukelekayo).
Ngaphansi kwesizukulwane sesibili vs Anti-anti-anti-anti-anti-antigenistamines yokuqala
Inzuzo ye-antihistamines yesibili yesizukulwane (i-Zyrtec no-Xyzal) ukungabi nemiphumela emibi engafuneki njenge-sedation, ukulala, nobunzima ekugxileni nasekufundeni.
Lemiphumela emibi iyakhathazeka ngokukhethekile lapho izingane ezineminyaka esikoleni ziphathwa ngezikhathi eside ne-hydroxyzine.
I-Xyzal (levocetirizine) yiyona kuphela i-antihistamine engenazo izimo ezimbi emitholampilo ekuthuthukiseni ngokomzimba nangokwengqondo ezinganeni ezineminyaka eyisithupha kuya eminyakeni engu-12, ngokusho kwezifundo.
Lokho kusho ukuthi i-hydroxyzine iyaqhubeka ingenalo ukungezwani komzimba okusetshenziselwa ukwelashwa kokukhathazeka okuncane, ukulala, nokuhlanza nokuhlanza. Kungaba futhi imithi engabizi kakhulu yesikhathi esifushane kubantu abadala abanezifo lapho imithwalo emibi ye-sedation ingaba nenzuzo (njengokungalali noma ukukhathazeka.)
> Imithombo:
> Pampura, A., Papadopoulos, N., Spicak, V., no R. Kurzawa. Ubufakazi bokuthi ukuphepha komtholampilo, ukuphumelela, kanye nomqondo womzali kanye nodokotela weLevocetirizine for the Treatment of the Children With Disease Illness. I-Archives Yomhlaba Wonke Yokuzifola Kwegazi Ne-Immunology . 2011. 155 (4): 367-78.